Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Catherine M Broome

Showing results (1-10 of 30) with videos related to

Pageof 3
Sort By:
Clinical Advances in Hematology & Oncology : H&O|July 1, 2025
Monotherapy with upstream or alternative pathway inhibitorsCatherine M Broome
Clinical Advances in Hematology & Oncology : H&O|April 11, 2019
Diagnosis and treatment of cold agglutinin diseaseCatherine M Broome
Clinical Advances in Hematology & Oncology : H&O|July 1, 2025
Dual therapy: danicopan as add-on therapy to C5 inhibitorsCatherine M Broome
Expert Review of Hematology|May 31, 2023
Complement-directed therapy for cold agglutinin disease: sutimlimabCatherine M Broome
Clinical Advances in Hematology & Oncology : H&O|July 1, 2025
Practical approach to managing PNH: Q&AGloria F Gerber, Ilene C Weitz, Catherine M Broome
Clinical Advances in Hematology & Oncology : H&O|April 20, 2013
Safe and effective treatment of aggressive non-hodgkin lymphoma with rituximab and bendamustine in patients with severe liver impairmentJames K McCloskey, Catherine M Broome, Bruce D Cheson
Clinical Advances in Hematology & Oncology : H&O|July 1, 2025
Navigating the paroxysmal nocturnal hemoglobinuria (PNH) landscapeGloria F Gerber, Catherine M Broome, Ilene C Weitz
Lancet (London, England)|August 3, 2024
Efgartigimod for primary immune thrombocytopenia: the ADVANCE IV trial - Authors' replyHanny Al-Samkari, James B Bussel, Yoshi Miyakawa, et al.
American Journal of Hematology|March 9, 2024
The latest insights into rare blood disorders: Diagnosis and treatment strategiesDavid J Kuter, Spero R Cataland, Catherine M Broome, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2002
Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancerDavid J Vaughn, Catherine M Broome, Maha Hussain, et al.
Pageof 3

Showing results (1-10 of 30) with videos related to

Sort By:
Pageof 3
Clinical Advances in Hematology & Oncology : H&O|July 1, 2025
Monotherapy with upstream or alternative pathway inhibitorsCatherine M Broome
Clinical Advances in Hematology & Oncology : H&O|April 11, 2019
Diagnosis and treatment of cold agglutinin diseaseCatherine M Broome
Clinical Advances in Hematology & Oncology : H&O|July 1, 2025
Dual therapy: danicopan as add-on therapy to C5 inhibitorsCatherine M Broome
Expert Review of Hematology|May 31, 2023
Complement-directed therapy for cold agglutinin disease: sutimlimabCatherine M Broome
Clinical Advances in Hematology & Oncology : H&O|July 1, 2025
Practical approach to managing PNH: Q&AGloria F Gerber, Ilene C Weitz, Catherine M Broome
Clinical Advances in Hematology & Oncology : H&O|April 20, 2013
Safe and effective treatment of aggressive non-hodgkin lymphoma with rituximab and bendamustine in patients with severe liver impairmentJames K McCloskey, Catherine M Broome, Bruce D Cheson
Clinical Advances in Hematology & Oncology : H&O|July 1, 2025
Navigating the paroxysmal nocturnal hemoglobinuria (PNH) landscapeGloria F Gerber, Catherine M Broome, Ilene C Weitz
Lancet (London, England)|August 3, 2024
Efgartigimod for primary immune thrombocytopenia: the ADVANCE IV trial - Authors' replyHanny Al-Samkari, James B Bussel, Yoshi Miyakawa, et al.
American Journal of Hematology|March 9, 2024
The latest insights into rare blood disorders: Diagnosis and treatment strategiesDavid J Kuter, Spero R Cataland, Catherine M Broome, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2002
Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancerDavid J Vaughn, Catherine M Broome, Maha Hussain, et al.
Pageof 3